European regulators to review Valneva shot; Jazz's stock dips on subpar first-quarter revenue

Plus, news about NewAmsterdam, C4 Therapeutics, Vivo Capital, and Arcus Biosciences: EMA to conduct safety review of Valneva vaccine: European regulators will review Ixchiq, Valneva’s live attenuated ...

Related Posts

Exclusive: Axiom raises $15M to build AI models for dru...

Apr 28, 2025  0

FDA approves Satsuma's migraine nasal spray after rejec...

May 1, 2025  0

AstraZeneca, Novartis execute ‘US for US’ strategy as p...

Apr 29, 2025  0

Comments

Name

Email

Comment

Post Comment